BioCentury
ARTICLE | Clinical News

Ligand preclinical data

July 15, 2013 7:00 AM UTC

In a mouse model of Type I diabetes, oral LGD-6972 for 28 days significantly reduced fasting blood glucose levels to 234 mg/dL vs. 382 mg/dL for vehicle-treated controls and 118 mg/dL for non-diabetic...